Toshiba strikes PACS deal with Agfa
Toshiba America Medical Systems and Agfa have signed a value-addedreseller agreement in which Toshiba will be able to sell Agfa'sImpax PACS line in situations where it is also selling multimodalityequipment. The nonexclusive deal finally gives Tustin,
Toshiba America Medical Systems and Agfa have signed a value-addedreseller agreement in which Toshiba will be able to sell Agfa'sImpax PACS line in situations where it is also selling multimodalityequipment. The nonexclusive deal finally gives Tustin, CA-basedToshiba a PACS line to compete with those of its multimodalitycompetitors.
Toshiba plans to use the deal to leverage sales of imagingequipment, rather than become a PACS vendor, according to LeslieFerrini, manager of Toshiba's connectivity systems group, whichwas formed earlier this year. The agreement is restricted to theU.S. at present.
For Agfa, the relationship gives it another distribution channelfor the Impax line, according to John Glass, Agfa's senior vicepresident of technical imaging. Toshiba becomes the RidgefieldPark, NJ, company's second multimodality OEM, following a dealwith Elscint signed last year (SCAN 11/22/95). Agfa will probablypursue more OEM deals, Glass said.
Toshiba and Agfa are collaborating on a PACS installation commissionedby Genesys Hospital System. Genesys is building a new facilityin Grand Blanc, MI, called Health Park, which will be filmlesswhen it opens in February. Last month's agreement formalizes therelationship that began at Genesys, according to Ferrini.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
